Histochemistry

, Volume 99, Issue 1, pp 61–66

Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells

Authors

  • R. Riesenberg
    • Urologische Klinik im Klinikum Großhadern
  • R. Oberneder
    • Urologische Klinik im Klinikum Großhadern
  • M. Kriegmair
    • Urologische Klinik im Klinikum Großhadern
  • M. Epp
    • Urologische Klinik im Klinikum Großhadern
  • U. Bitzer
    • Urologische Klinik im Klinikum Großhadern
  • A. Hofstetter
    • Urologische Klinik im Klinikum Großhadern
  • S. Braun
    • Institut für ImmunologieLudwig-Maximilians-Universität München
  • G. Riethmüller
    • Institut für ImmunologieLudwig-Maximilians-Universität München
  • K. Pantel
    • Institut für ImmunologieLudwig-Maximilians-Universität München
Originals

DOI: 10.1007/BF00268022

Cite this article as:
Riesenberg, R., Oberneder, R., Kriegmair, M. et al. Histochemistry (1993) 99: 61. doi:10.1007/BF00268022

Abstract

Early dissemination of malignant cells is the main cause for metastatic relapse in patients with solid tumours. By use of monoclonal antibodies (mAbs) specific for cytokeratins, disseminated individual epithelial tumour cells can now be identified in mesenchymal organs such as bone marrow. Further to characterize such cells in patients with prostate cancer, an immunocytochemical procedure was developed for simultaneous labelling of cytokeratin component no. 18 (CK18) and prostate specific antigen (PSA). In a first step, cells were incubated with mAb ER-PR8 against PSA and secondary gold-conjugated goat anti-mouse antibodies. In a second step, biotinylated mAb CK2 to CK18 was applied as primary antibody and subsequently incubated with complexes of streptavidin-conjugated alkaline phosphatase, which were developed with the Newfuchsin substrate. The binding of gold-labelled antibodies was visualized by silver enhancement. The sensitivity and specificity of the technique was demonstrated on cryostat sections of hyperplastic prostatic tissue, and cytological preparations of LNCaP prostatic tumour cells. Double staining was restricted to cells derived from the secretory epithelium of the prostate. Cross-reactivity between both detection systems was excluded by several controls, including the use of unrelated antibodies of the same isotype and the staining of CK18+/PSA HT29 colon carcinoma cells. CK18+ cells co-expressing PSA were found in bone marrow aspirates from 5 out of 13 patients with carcinomas of the prostate, a finding that is consistent with the relative fraction of double-positive LNCaP cells. The specificity of CK18 for epithelial tumour cells in bone marrow was supported by negative staining of 12 control aspirates from patients with benign prostatic hypertrophy. In conclusion, the approach presented appears to be a reliable method to phenotype individual prostatic carcinoma cells.

Copyright information

© Springer-Verlag 1993